# Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers

> **NCT05735496** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.** · enrollment: 219 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** TQB2102 injection

## Key facts

- **NCT ID:** NCT05735496
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-03-09
- **Primary completion:** 2025-07-21
- **Final completion:** 2027-07
- **Target enrollment:** 219 (ACTUAL)
- **Last updated:** 2025-08-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05735496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05735496, "Clinical Trial of the TQB2102 Injection in Patients With Advanced Cancers". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05735496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*